![a portrait photo of a man in a suit](/sites/default/files/styles/article_headlines/public/2024-03/britz-headshot.jpg?itok=1jnCCwFV)
Please do not leave this page until complete. This can take a few moments.
Less than four months after hiring its first CEO in company history, Natick-based biopharmaceutical company AffyImmune Therapeutics has a new leader.
Daniel Janse, a former independent consultant and former managing director of Cambridge-based venture capital firm Northpond Ventures, has been named the CEO and president of the firm, replacing Matt Britz, who was named the company’s first-ever CEO in March.
In addition to his time at Northpond, Janse has served on the board of several biotech companies, including Cambridge-based Garuda Therapeutics and EnPlusOne Biosciences, a firm based in Watertown, according to an AffyImmune press release issued Monday. He holds a Ph.D. in biological sciences from Harvard University.
“I am honored to join AffyImmune at such a pivotal time in the company’s journey,” Janse said in the press release. “I look forward to working with the team and board of directors to continue and expedite the development of AIC100 for patients with advanced thyroid cancers and non-small-cell lung cancer.”
The company declined to provide more details regarding Brtiz’s departure in an email to WBJ. Britz had joined AffyImmune as its senior vice president, business development in June 2021, according to a press release issued by the company in March following his appointment as CEO.
AffyImmune is working to develop CAR T cell therapies, which utilizes patients’ own immune systems to target and destroy cancer cells. The company is the first to demonstrate the potential of single-dose, single-agent autologous CAR T to induce a complete response in a patient with an anaplastic thyroid cancer tumor, according to its Monday press release.
The company has 11 local employees and 24 employees company-wide, according to data submitted by the company to the WBJ Research Department.
“We are thrilled to welcome Dr. Janse as the new CEO of AffyImmune,” Simone Song, founding partner of ORI Capital and board director at AffyImmune, said in the press release. “His extensive experience in the biotech industry and his proven leadership in driving innovation and strategic growth make him the ideal executive to lead AffyImmune into its next phase of growth.“
Song’s ORI Capital, an investment firm with offices in Natick and Hong Kong, raised $260 million in February to support investments into biotechnology companies in its portfolio, which includes AffyImmune.
Eric Casey is a staff writer at Worcester Business Journal, who primarily covers the manufacturing and real estate industries.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments